Benign Prostatic Hyperplasia (BPH) and Acupuncture

Deep Dive

From a Western clinical standpoint, BPH reflects age‑related prostatic hyperplasia driven in part by dihydrotestosterone and local growth signal... From a Western clinical standpoint, BPH reflects age‑related prostatic hyperplasia driven in part by dihydrotestosterone and local growth signals. The resulting increase in outlet resistance, along with concomitant bladder changes, produces LUTS that impair sleep and quality of life. Standard care ranges from behavioral strategies and medications (alpha‑blockers, 5‑alpha‑reductase inhibitors, PDE‑5 inhibitors) to procedures for refractory or complicated disease. Within this framework, acupuncture is evaluated as an adjunctive, nonpharmacologic symptom‑management option. Randomized trials and pooled analyses suggest acupuncture can reduce IPSS scores more than sham or usual care over 4–8 weeks, with small but measurable gains in Qmax and nocturia. However, effect sizes vary, and methodological limitations—heterogeneous point prescriptions, variable sham controls, and modest sample sizes—temper certainty. Objective anatomic measures such as prostate volume and post‑void residual typically remain unchanged, implying acupuncture’s effects are functional, likely mediated through neuromodulation rather than gland size reduction. Mechanistically, acupuncture may influence lower urinary tract function via modulation of autonomic balance (shifting sympathetic/parasympathetic tone), segmental spinal pathways related to the sacral plexus, and central control centers for micturition. Additional hypotheses include increased pelvic microcirculation and anti‑inflammatory signaling, though direct hormonal effects on androgens are not demonstrated. Safety data are reassuring, with mostly minor, transient adverse events. Clinically, acupuncture may be considered to complement lifestyle strategies and pharmacotherapy, particularly for patients seeking to reduce nocturia or urgency while avoiding additional medications. It is not a substitute for urologic evaluation when red flags are present (retention, recurrent infections, hematuria, renal impairment) and has not been shown to prevent BPH progression or complications. Future high‑quality, sham‑controlled trials with standardized protocols and longer follow‑up are needed to clarify who benefits most, durability, and cost‑effectiveness.